News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

All Stories

News

Big Money for Gene Editing, Engineering, Structure-Based Drug Design, and Data Management

April 30, 2021

Bio IT World

Read Now

Press Release

Big Money for Gene Editing, Engineering, Structure-Based Drug Design, and Data Management

April 30, 2021

Bio IT World

Read Now

News

5 Novel Therapies Using Synthetic Biology

April 12, 2021

Nanalyze

Read Now

Press Release

5 Novel Therapies Using Synthetic Biology

April 12, 2021

Nanalyze

Read Now

News

Engineering CRISPR with Ben Oakes

April 8, 2021

Andreessen Horowitz

Read Now

Press Release

Engineering CRISPR with Ben Oakes

April 8, 2021

Andreessen Horowitz

Read Now

News

The 20(+1) under 40: Inside the next generation of biotech leaders

April 6, 2021

Endpoints News

Read Now

Press Release

The 20(+1) under 40: Inside the next generation of biotech leaders

April 6, 2021

Endpoints News

Read Now

News

Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline

April 1, 2021

PMLive

Read Now

Press Release

Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline

April 1, 2021

PMLive

Read Now

Press Release

Scribe Therapeutics Raises $100M Series B Financing to Further Develop 'CRISPR by Design' Platform and Pipeline of Breakthrough Genetic Medicines

March 31, 2021

Read Now

Press Release

Scribe Therapeutics Raises $100M Series B Financing to Further Develop 'CRISPR by Design' Platform and Pipeline of Breakthrough Genetic Medicines

March 31, 2021

Read Now

News

Scribe Therapeutics plans to test cholesterol-lowering epigenetic editing therapy

January 14, 2026

Endpoints

Read Now

News

CRISPR Slashes ‘Bad Cholesterol’ Levels by 95 Percent in Early Results

November 27, 2025

Singularity Hub

Read Now

News

Can AI take the guesswork out of CRISPR?

November 24, 2025

Drug Discovery News

Read Now

News

Can genetic medicine solve cardiovascular disease?

November 20, 2025

Longevity.Technology

Read Now

News

Scribe eyes clinic after CRISPR candidates lower lipids in animals

November 17, 2025

Fierce Biotech

Read Now

News

Epigenetic approach shows durable PCSK9 silencing in primates

October 15, 2025

BioWorld

Read Now

Press release

Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi

January 13, 2025

Read Now

Press release

Scribe Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 9, 2025

Read Now

Press release

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Read Now

Press release

Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024

October 30, 2024

Read Now

Press release

Scribe Therapeutics to Participate in Upcoming Conferences

September 12, 2024

Read Now

Press release

Scribe Therapeutics Presents Data Demonstrating Highly Potent Gene Editing In Vivo, Including Saturated Editing of Hepatocytes in NHPs, by an Engineered XE Genome Editor; Showcases Novel Epigenetic Editing Capabilities at 2024 ASGCT Annual Meeting

May 10, 2024

Read Now

Publications and presentations

Publication

Engineered Allosteric Control Enhances Specificity and Potency of CRISPR-CasX-based Epigenetic Repressors

January 14, 2026

bioRxiv

Read Now

Publication

Single particle charge detection mass spectrometry enables molecular characterization of lipid nanoparticles and mRNA packaging

May 18, 2025

Journal of Controlled Release

Read Now

Publication

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Read Now

Publication

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Read Now

Publication

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Read Now

Publication

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Read Now

Publication

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Read Now

Publication

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Read Now

Publication

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

Read Now

Publication

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature

Read Now